FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hiromitsu Fujishima

Research Profile

Chemicals & Drugs

Procedures

Antineoplastic Combined Chemotherapy Protocols

Genes & Molecular Sequences

Genes, src

Disorders

Co-author Network

Publications

TOP 3
Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Akitaka Makiyama; Kenji Mitsugi; Shuji Nakano; Risa Tanaka; Keita Uchino; Koichi Akashi
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Kenji Mitsugi; Tatsuma Morikita; Shuji Nakano; Hiroshi Ariyama; Koichi Akashi
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Hitoshi Kusaba; Taito Esaki; Kitaro Futami; Sinnosuke Tanaka; Hiromitsu Fujishima; Kenji Mitsugi; Kenji Sakai; Hiroshi Ariyama; Risa Tanaka; Naoko Kinugawa; Takashi Ueki; Rhuichi Mibu; Eishi Baba; Shuji Nakano; Koichi Akashi
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hiromitsu Fujishima (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Akitaka Makiyama; Kenji Mitsugi; Shuji Nakano; Risa Tanaka; Keita Uchino; Koichi Akashi
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Advances in therapy 2012;29(3):287-96.
2011: Eishi Baba; Taito Esaki; Hiromitsu Fujishima; Hitoshi Kusaba; Kenji Mitsugi; Tatsuma Morikita; Shuji Nakano; Hiroshi Ariyama; Koichi Akashi
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Cancer chemotherapy and pharmacology 2011;68(3):611-7.
2010: Hitoshi Kusaba; Taito Esaki; Kitaro Futami; Sinnosuke Tanaka; Hiromitsu Fujishima; Kenji Mitsugi; Kenji Sakai; Hiroshi Ariyama; Risa Tanaka; Naoko Kinugawa; Takashi Ueki; Rhuichi Mibu; Eishi Baba; Shuji Nakano; Koichi Akashi
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Cancer science 2010;101(12):2591-5.
2009: Eishi Baba; Hiromitsu Fujishima; Hitoshi Kusaba; Taito Esaki; Hiroshi Ariyama; Ken Kato; Risa Tanaka; Kenji Mitsugi; Yoshihiro Shibata; Mine Harada; Shuji Nakano
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Anticancer research 2009;29(5):1727-32.
2004: Hiromitsu Fujishima; Ikuo Kikuchi; Osamu Miyanaga; Akira Ueda; Eishi Baba; Kenji Mitsugi; Mine Harada; Shuji Nakano
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
International journal of clinical oncology 2004;9(2):92-7.
2003: Chizuko Hisano; Risa Tanaka; Hiromitsu Fujishima; Hiroshi Ariyama; Tanji Tsuchiya; Takashi Tatsumoto; Kenji Mitsugi; Minoru Nakamura; Shuji Nakano
Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells.
Cell biology international 2003;27(5):415-21.
1999: Naoko Masumoto; Shuji Nakano; Hiromitsu Fujishima; Kimitoshi Kohno; Yoshiyuki Niho
v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
International journal of cancer. Journal international du cancer 1999;80(5):731-7.
1998: Hiromitsu Fujishima; Shuji Nakano; Takashi Tatsumoto; Naoko Masumoto; Yoshiyuki Niho
Interferon-alpha and -gamma inhibit the growth and neoplastic potential of v-src-transformed human epithelial cells by reducing Src tyrosine kinase activity.
International journal of cancer. Journal international du cancer 1998;76(3):423-9.
1997: Hiromitsu Fujishima; Shuji Nakano; Naoko Masumoto; T Esaki; Takashi Tatsumoto; T Kondo; Yoshiyuki Niho
Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Oncology research 1997;9(4):167-72.
1996: C Hisano; Shuji Nakano; K Okuma; Naoko Masumoto; Hiromitsu Fujishima; M Nakamura; Y Niho
[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
Gan to kagaku ryoho. Cancer & chemotherapy 1996;23(9):1175-81.
1996: T Esaki; Shuji Nakano; Naoko Masumoto; Hiromitsu Fujishima; Y Niho
Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
International journal of cancer. Journal international du cancer 1996;65(4):479-84.
1995: Naoko Masumoto; Shuji Nakano; T Esaki; Hiromitsu Fujishima; T Tatsumoto; Y Niho
Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
International journal of cancer. Journal international du cancer 1995;62(1):70-5.
1995: Naoko Masumoto; Shuji Nakano; T Esaki; T Tatsumoto; Hiromitsu Fujishima; Eishi Baba; M Nakamura; Y Niho
Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.
Anticancer research 1995;15(2):405-9.
1994: Hiromitsu Fujishima; K Mitsugi; M Nakamura; H Yoshimatsu; Shuji Nakano; Y Niho
[A case of advanced gastric cancer complicated with multiple liver metastasis successfully treated with l-LV and 5-FU combination].
Gan to kagaku ryoho. Cancer & chemotherapy 1994;21(6):869-72.